テキサスにおける急性二系統白血病の臨床試験
テキサス内の拠点で、急性二系統白血病に関する13件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
12歳〜78歳 · 全性別 · 2026/09/29更新 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他7件
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03683433Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他12件
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他10件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
被験者募集中第1相
1歳〜30歳 · 全性別 · 2026/08/03更新 · NCT06177067Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
被験者募集中第2相
15歳〜80歳 · 全性別 · 2026/07/30更新 · NCT02727803A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/06/22更新 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT04047641Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/05/20更新 · NCT02115295The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。